American Cancer Society Recommends PSA Testing Schedule by Risk Level

The American Cancer Society replaced its 2010 guidance with a direct schedule: average-risk men ages 50 to 69 should get a PSA blood test every two years, while Black men and those with a strong family history should start annual testing at 45.

The shift, published Thursday in CA: A Cancer Journal for Clinicians, ends 16 years of recommending only a shared decision-making conversation. The guideline development group, chaired by Dr. Andrew Wolf of the University of Virginia School of Medicine, concluded that stronger evidence shows screening benefits — fewer advanced-stage diagnoses and lower mortality — outweigh harms of overdiagnosis and overtreatment.

“For the first time, we are making a proactive recommendation for men to screen for prostate cancer with the prostate-specific antigen blood test,” said Wolf, professor emeritus of medicine at the University of Virginia School of Medicine and chair of the American Cancer Society’s Guideline Development Group.

Wolf, professor emeritus of medicine at UVA and chair of the ACS Guideline Development Group. “It’s now clear that the benefits of screening in terms of reducing the risk of dying from prostate cancer or being diagnosed with late-stage disease outweigh the potential downsides of the screening.”

Risk-Based Schedule Replaces Shared Decision-Making

The new guideline stratifies recommendations by risk level, a departure from the previous one-size-fits-all conversation. Average-risk men — non-Black men without a family history — should begin biennial PSA testing at 50 and continue through 69.

Black men should start annual screening at 45. So should non-Black men with multiple first-degree relatives diagnosed at any age or one diagnosed before 65. Men with a single first-degree relative diagnosed at 65 or older follow a biennial schedule starting at 45.

American Cancer Society Recommends PSA Testing Schedule by Risk Level
Photo: American Cancer Society Press Room

For men 70 to 74, benefits and harms remain uncertain, leaving the decision to individual discussion. Screening is not recommended for men 75 and older, or for anyone not expected to live another 10 years.

Addressing Racial Disparity

The recommendation for earlier, annual screening in Black men is driven by data showing a 67% higher incidence and nearly double the mortality rate compared with White men.

“Black men experience a 67% higher incidence and nearly double the mortality rate compared with White men, an inequity that needs immediate reversal,” said Dr. William Dahut, chief scientific officer for the ACS. He said Black men develop prostate cancer at younger ages and their cancers tend to progress more rapidly.

The society estimates 333,830 new U.S. cases and 36,320 deaths in 2026, making prostate cancer the second-leading cause of cancer death in men after lung cancer. The guideline cites modeling studies and long-term follow-up from the European Randomized Study of Screening for Prostate Cancer.

Managing Screening Harms

The guideline pairs its schedule with a clinical pathway to reduce unnecessary biopsies and treatment of low-risk disease. Before starting, clinicians must ensure patients understand benefits, limitations and potential harms — including false positives and follow-up cascades. An elevated PSA should trigger a repeat test in two weeks to three months, followed by MRI or biomarker testing to determine whether a biopsy is warranted.

Symptom check prostate cancer mh
Photo: TODAY.com

“PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits,” said Dr. Robert Smith, director of the Center for Early Cancer Detection at the American Cancer Society. “We also have better approaches to catching lethal tumors while avoiding unnecessary tests for slow-growing cancers that may never need aggressive care.”

Men diagnosed with low-risk cancer should be offered active surveillance as the initial management strategy, the guideline states, reflecting widespread adoption of protocols that monitor rather than immediately treat indolent disease.

Living Guideline Contrasts With Canada's Frozen Recommendations

The ACS designated this a “living guideline”, meaning its scientists and volunteers will continuously monitor new evidence and update recommendations periodically. That approach contrasts with Canada, where the national advisory body’s clinical guidelines have not been updated since 2014 and still recommend against routine PSA screening.

The Canadian Cancer Society issued an open letter in September urging modernization, noting that “what we have now is a guideline that is frozen in time from over a decade ago, and increasingly out of step with contemporary clinical practice.”

Medicare Part B currently covers one PSA test annually for men over 50 with no cost for the test itself.